메뉴 건너뛰기




Volumn 8, Issue 32, 2017, Pages 53854-53872

Strategies targeting angiogenesis in advanced non-small cell lung cancer

Author keywords

Angiogenesis; Antiangiogenic agents; Bevacizumab; NSCLC

Indexed keywords


EID: 85029541212     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17957     Document Type: Article
Times cited : (58)

References (117)
  • 2
    • 84855955174 scopus 로고    scopus 로고
    • Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC)
    • Klastersky J, Awada A. Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 2012; 81:49-57.
    • (2012) Crit Rev Oncol Hematol , vol.81 , pp. 49-57
    • Klastersky, J1    Awada, A.2
  • 4
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
    • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12:735-742.
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C1    Wu, YL2    Chen, G3    Feng, J4    Liu, XQ5    Wang, C6    Zhang, S7    Wang, J8    Zhou, S9    Ren, S10    Lu, S11    Zhang, L12    Hu, C13
  • 7
    • 84976285844 scopus 로고    scopus 로고
    • Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    • Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther. 2016; 9:3711-3726.
    • (2016) Onco Targets Ther , vol.9 , pp. 3711-3726
    • Wang, J1    Wang, B2    Chu, H3    Yao, Y.4
  • 8
    • 84857882376 scopus 로고    scopus 로고
    • Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
    • Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012; 13:247-263.
    • (2012) Cancer Biol Ther , vol.13 , pp. 247-263
    • Aggarwal, C1    Somaiah, N2    Simon, G.3
  • 9
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: the next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D1    Weinberg, RA.2
  • 10
    • 0035432151 scopus 로고    scopus 로고
    • Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy
    • Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int J Oncol. 2001; 19:257-262.
    • (2001) Int J Oncol , vol.19 , pp. 257-262
    • Blagosklonny, MV.1
  • 11
    • 84859415553 scopus 로고    scopus 로고
    • Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
    • Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18:1855-1862.
    • (2012) Clin Cancer Res , vol.18 , pp. 1855-1862
    • Brooks, AN1    Kilgour, E2    Smith, PD.3
  • 12
    • 0345798150 scopus 로고    scopus 로고
    • Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors
    • Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest. 2003, 112:1142-1151.
    • (2003) J Clin Invest , vol.112 , pp. 1142-1151
    • Abramsson, A1    Lindblom, P2    Betsholtz, C.3
  • 13
    • 63749125392 scopus 로고    scopus 로고
    • VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
    • Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009; 21:154-165.
    • (2009) Curr Opin Cell Biol , vol.21 , pp. 154-165
    • Lohela, M1    Bry, M2    Tammela, T3    Alitalo, K.4
  • 16
    • 1642472018 scopus 로고    scopus 로고
    • Antiangiogenic therapy and tumor progression
    • Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5:13-17.
    • (2004) Cancer Cell , vol.5 , pp. 13-17
    • Blagosklonny, MV.1
  • 17
    • 33747855481 scopus 로고    scopus 로고
    • Comparing antibody and small-molecule therapies for cancer
    • Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6:714-727.
    • (2006) Nat Rev Cancer , vol.6 , pp. 714-727
    • Imai, K1    Takaoka, A.2
  • 18
    • 2942657615 scopus 로고    scopus 로고
    • Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    • Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22:2184-2191.
    • (2004) J Clin Oncol , vol.22 , pp. 2184-2191
    • Johnson, DH1    Fehrenbacher, L2    Novotny, WF3    Herbst, RS4    Nemunaitis, JJ5    Jablons, DM6    Langer, CJ7    DeVore, RF8    Gaudreault, J9    Damico, LA10    Holmgren, E11    Kabbinavar, F.12
  • 20
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
    • Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27:1227-1234.
    • (2009) J Clin Oncol , vol.27 , pp. 1227-1234
    • Reck, M1    von Pawel, J2    Zatloukal, P3    Ramlau, R4    Gorbounova, V5    Hirsh, V6    Leighl, N7    Mezger, J8    Archer, V9    Moore, N10    Manegold, C.11
  • 21
    • 77951473661 scopus 로고    scopus 로고
    • Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    • BO17704 Study Group
    • Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010; 21:1804-1809.
    • (2010) Ann Oncol , vol.21 , pp. 1804-1809
    • Reck, M1    von Pawel, J2    Zatloukal, P3    Ramlau, R4    Gorbounova, V5    Hirsh, V6    Leighl, N7    Mezger, J8    Archer, V9    Moore, N10    Manegold, C.11
  • 22
    • 84860505684 scopus 로고    scopus 로고
    • Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced nonsquamous non-small-cell lung cancer
    • Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced nonsquamous non-small-cell lung cancer. Lung cancer. 2012; 76:362-367.
    • (2012) Lung cancer , vol.76 , pp. 362-367
    • Niho, S1    Kunitoh, H2    Nokihara, H3    Horai, T4    Ichinose, Y5    Hida, T6    Yamamoto, N7    Kawahara, M8    Shinkai, T9    Nakagawa, K10    Matsui, K11    Negoro, S12    Yokoyama, A13
  • 23
    • 84937117699 scopus 로고    scopus 로고
    • BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/ Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
    • 2 et l
    • Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C2, Zhang H, et l. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/ Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33:2197-2204.
    • (2015) J Clin Oncol , vol.33 , pp. 2197-2204
    • Zhou, C1    Wu, YL2    Chen, G3    Liu, X4    Zhu, Y5    Lu, S6    Feng, J7    He, J8    Han, B9    Wang, J10    Jiang, G11    Hu, C12    Zhang, H13
  • 24
    • 77955268612 scopus 로고    scopus 로고
    • Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
    • Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010; 11:733-740.
    • (2010) Lancet Oncol , vol.11 , pp. 733-740
    • Crinò, L1    Dansin, E2    Garrido, P3    Griesinger, F4    Laskin, J5    Pavlakis, N6    Stroiakovski, D7    Thatcher, N8    Tsai, CM9    Wu, YL10    Zhou, C.11
  • 25
    • 79958164295 scopus 로고    scopus 로고
    • Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study
    • Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study. J Thorac Oncol. 2011; 6:1092-1097.
    • (2011) J Thorac Oncol , vol.6 , pp. 1092-1097
    • Tsai, CM1    Au, JS2    Chang, GC3    Cheng, AC4    Zhou, C5    Wu, YL.6
  • 26
    • 84900802283 scopus 로고    scopus 로고
    • Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study
    • Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, Wu YL, Zhang YP, Zhu YZ. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol. 2014; 16:463-468.
    • (2014) Clin Transl Oncol , vol.16 , pp. 463-468
    • Zhou, CC1    Bai, CX2    Guan, ZZ3    Jiang, GL4    Shi, YK5    Wang, MZ6    Wu, YL7    Zhang, YP8    Zhu, YZ.9
  • 27
    • 80052607351 scopus 로고    scopus 로고
    • Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis
    • Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung cancer. 2011; 74:89-97.
    • (2011) Lung cancer , vol.74 , pp. 89-97
    • Botrel, TE1    Clark, O2    Clark, L3    Paladini, L4    Faleiros, E5    Pegoretti, B.6
  • 28
    • 84871538217 scopus 로고    scopus 로고
    • meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
    • Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP. meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013; 24:20-30.
    • (2013) Ann Oncol , vol.24 , pp. 20-30
    • Soria, JC1    Mauguen, A2    Reck, M3    Sandler, AB4    Saijo, N5    Johnson, DH6    Burcoveanu, D7    Fukuoka, M8    Besse, B9    Pignon, JP.10
  • 29
    • 79955565439 scopus 로고    scopus 로고
    • Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network
    • Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist. 2011; 16:486-496.
    • (2011) Oncologist , vol.16 , pp. 486-496
    • Nadler, E1    Yu, E2    Ravelo, A3    Sing, A4    Forsyth, M5    Gruschkus, S.6
  • 30
    • 84863084949 scopus 로고    scopus 로고
    • First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients
    • Leon L, Vazquez S, Gracia JM, Casal J, Lazaro M, Firvida JL, Amenedo M, Santome L, Macia S. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients. Expert Opin Pharmacother. 2012; 13:1389-1396.
    • (2012) Expert Opin Pharmacother , vol.13 , pp. 1389-1396
    • Leon, L1    Vazquez, S2    Gracia, JM3    Casal, J4    Lazaro, M5    Firvida, JL6    Amenedo, M7    Santome, L8    Macia, S.9
  • 32
    • 70249116447 scopus 로고    scopus 로고
    • Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer
    • Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009; 27: 3284-3289.
    • (2009) J Clin Oncol , vol.27 , pp. 3284-3289
    • Patel, JD1    Hensing, TA2    Rademaker, A3    Hart, EM4    Blum, MG5    Milton, DT6    Bonomi, PD.7
  • 33
    • 84886385462 scopus 로고    scopus 로고
    • Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)
    • Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013; 31:3004-3011.
    • (2013) J Clin Oncol , vol.31 , pp. 3004-3011
    • Barlesi, F1    Scherpereel, A2    Rittmeyer, A3    Pazzola, A4    Ferrer Tur, N5    Kim, JH6    Ahn, MJ7    Aerts, JG8    Gorbunova, V9    Vikström, A10    Wong, EK11    Perez-Moreno, P12    Mitchell, L13
  • 34
    • 84905822586 scopus 로고    scopus 로고
    • Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
    • Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014; 25:1044-1052.
    • (2014) Ann Oncol , vol.25 , pp. 1044-1052
    • Barlesi, F1    Scherpereel, A2    Gorbunova, V3    Gervais, R4    Vikström, A5    Chouaid, C6    Chella, A7    Kim, JH8    Ahn, MJ9    Reck, M10    Pazzola, A11    Kim, HT12    Aerts, JG13
  • 35
    • 84892454962 scopus 로고    scopus 로고
    • PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer
    • Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31:4349-4357.
    • (2013) J Clin Oncol , vol.31 , pp. 4349-4357
    • Patel, JD1    Socinski, MA2    Garon, EB3    Reynolds, CH4    Spigel, DR5    Olsen, MR6    Hermann, RC7    Jotte, RM8    Beck, T9    Richards, DA10    Guba, SC11    Liu, J12    Frimodt-Moller, B13
  • 36
    • 84926419605 scopus 로고    scopus 로고
    • PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
    • Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015; 10:134-142.
    • (2015) J Thorac Oncol , vol.10 , pp. 134-142
    • Zinner, RG1    Obasaju, CK2    Spigel, DR3    Weaver, RW4    Beck, JT5    Waterhouse, DM6    Modiano, MR7    Hrinczenko, B8    Nikolinakos, PG9    Liu, J10    Koustenis, AG11    Winfree, KB12    Melemed, SA13
  • 37
    • 36048982143 scopus 로고    scopus 로고
    • Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    • Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007; 25:4743-4750.
    • (2007) J Clin Oncol , vol.25 , pp. 4743-4750
    • Herbst, RS1    O'Neill, VJ2    Fehrenbacher, L3    Belani, CP4    Bonomi, PD5    Hart, L6    Melnyk, O7    Ramies, D8    Lin, M9    Sandler, A.10
  • 38
    • 80155141305 scopus 로고    scopus 로고
    • Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial
    • Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer. 2011; 12:407-411.
    • (2011) Clin Lung Cancer , vol.12 , pp. 407-411
    • Gridelli, C1    Bennouna, J2    de Castro, J3    Dingemans, AM4    Griesinger, F5    Grossi, F6    Rossi, A7    Thatcher, N8    Wong, EK9    Langer, C.10
  • 39
    • 84908139963 scopus 로고    scopus 로고
    • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    • Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15:1224-1235.
    • (2014) Lancet Oncol , vol.15 , pp. 1224-1235
    • Wilke, H1    Muro, K2    Van Cutsem, E3    Oh, SC4    Bodoky, G5    Shimada, Y6    Hironaka, S7    Sugimoto, N8    Lipatov, O9    Kim, TY10    Cunningham, D11    Rougier, P12    Komatsu, Y13
  • 40
    • 84933673498 scopus 로고    scopus 로고
    • Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
    • Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015; 16:499-508.
    • (2015) Lancet Oncol , vol.16 , pp. 499-508
    • Tabernero, J1    Yoshino, T2    Cohn, AL3    Obermannova, R4    Bodoky, G5    Garcia-Carbonero, R6    Ciuleanu, TE7    Portnoy, DC8    Van Cutsem, E9    Grothey, A10    Prausová, J11    Garcia-Alfonso, P12    Yamazaki, K13
  • 41
    • 84925706983 scopus 로고    scopus 로고
    • A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/ IV non-small-cell lung cancer
    • Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M Jr, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/ IV non-small-cell lung cancer. J Thorac Oncol. 2014; 9:1532-1539.
    • (2014) J Thorac Oncol , vol.9 , pp. 1532-1539
    • Camidge, DR1    Berge, EM2    Doebele, RC3    Ballas, MS4    Jahan, T5    Haigentz, M6    Hoffman, D7    Spicer, J8    West, H9    Lee, P10    Yang, L11    Joshi, A12    Gao, L13
  • 42
    • 84924207092 scopus 로고    scopus 로고
    • Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer
    • Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015; 121:883-892.
    • (2015) Cancer , vol.121 , pp. 883-892
    • Doebele, RC1    Spigel, D2    Tehfe, M3    Thomas, S4    Reck, M5    Verma, S6    Eakle, J7    Bustin, F8    Goldschmidt, J9    Cao, D10    Alexandris, E11    Yurasov, S12    Camidge, DR13
  • 43
    • 84906903314 scopus 로고    scopus 로고
    • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
    • Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384:665-673.
    • (2014) Lancet , vol.384 , pp. 665-673
    • Garon, EB1    Ciuleanu, TE2    Arrieta, O3    Prabhash, K4    Syrigos, KN5    Goksel, T6    Park, K7    Gorbunova, V8    Kowalyszyn, RD9    Pikiel, J10    Czyzewicz, G11    Orlov, SV12    Lewanski, CR13
  • 44
    • 84978802703 scopus 로고    scopus 로고
    • A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
    • Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung cancer. 2016; 99:186-193.
    • (2016) Lung cancer , vol.99 , pp. 186-193
    • Yoh, K1    Hosomi, Y2    Kasahara, K3    Yamada, K4    Takahashi, T5    Yamamoto, N6    Nishio, M7    Ohe, Y8    Koue, T9    Nakamura, T10    Enatsu, S11    Lee, P12    Ferry, D13
  • 45
    • 80051638135 scopus 로고    scopus 로고
    • Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
    • Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29:2965-2971.
    • (2011) J Clin Oncol , vol.29 , pp. 2965-2971
    • Lara, PN1    Douillard, JY2    Nakagawa, K3    von Pawel, J4    McKeage, MJ5    Albert, I6    Losonczy, G7    Reck, M8    Heo, DS9    Fan, X10    Fandi, A11    Scagliotti, G.12
  • 46
    • 84867602821 scopus 로고    scopus 로고
    • Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial
    • Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012; 30:3640-3647.
    • (2012) J Clin Oncol , vol.30 , pp. 3640-3647
    • Ramlau, R1    Gorbunova, V2    Ciuleanu, TE3    Novello, S4    Ozguroglu, M5    Goksel, T6    Baldotto, C7    Bennouna, J8    Shepherd, FA9    Le-Guennec, S10    Rey, A11    Miller, V12    Thatcher, N13
  • 48
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    • Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10:25-34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, AL1    Kang, YK2    Chen, Z3    Tsao, CJ4    Qin, S5    Kim, JS6    Luo, R7    Feng, J8    Ye, S9    Yang, TS10    Xu, J11    Sun, Y12    Liang, H13
  • 50
    • 84865721505 scopus 로고    scopus 로고
    • Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/ cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
    • Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/ cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012; 30:3084-3092.
    • (2012) J Clin Oncol , vol.30 , pp. 3084-3092
    • Paz-Ares, LG1    Biesma, B2    Heigener, D3    von Pawel, J4    Eisen, T5    Bennouna, J6    Zhang, L7    Liao, M8    Sun, Y9    Gans, S10    Syrigos, K11    Le Marie, E12    Gottfried, M13
  • 52
    • 79955795090 scopus 로고    scopus 로고
    • A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
    • Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011; 22:2057-2067.
    • (2011) Ann Oncol , vol.22 , pp. 2057-2067
    • Blumenschein, GR1    Kabbinavar, F2    Menon, H3    Mok, TS4    Stephenson, J5    Beck, JT6    Lakshmaiah, K7    Reckamp, K8    Hei, YJ9    Kracht, K10    Sun, YN11    Sikorski, R12    Schwartzberg, L.13
  • 53
    • 42949105645 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group
    • Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2008; 26:1871-1878.
    • (2008) J Clin Oncol , vol.26 , pp. 1871-1878
    • Laurie, SA1    Gauthier, I2    Arnold, A3    Shepherd, FA4    Ellis, PM5    Chen, E6    Goss, G7    Powers, J8    Walsh, W9    Tu, D10    Robertson, J11    Puchalski, TA12    Seymour, L.13
  • 54
    • 73949092851 scopus 로고    scopus 로고
    • Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
    • Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 2010; 28:49-55.
    • (2010) J Clin Oncol , vol.28 , pp. 49-55
    • Goss, GD1    Arnold, A2    Shepherd, FA3    Dediu, M4    Ciuleanu, TE5    Fenton, D6    Zukin, M7    Walde, D8    Laberge, F9    Vincent, MD10    Ellis, PM11    Laurie, SA12    Ding, K13
  • 55
    • 84894041073 scopus 로고    scopus 로고
    • Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
    • Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014; 50:706-712.
    • (2014) Eur J Cancer , vol.50 , pp. 706-712
    • Laurie, SA1    Solomon, BJ2    Seymour, L3    Ellis, PM4    Goss, GD5    Shepherd, FA6    Boyer, MJ7    Arnold, AM8    Clingan, P9    Laberge, F10    Fenton, D11    Hirsh, V12    Zukin, M13
  • 56
    • 84871977845 scopus 로고    scopus 로고
    • A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528
    • Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol. 2013; 8:79-88.
    • (2013) J Thorac Oncol , vol.8 , pp. 79-88
    • Dy, GK1    Mandrekar, SJ2    Nelson, GD3    Meyers, JP4    Adjei, AA5    Ross, HJ6    Ansari, RH7    Lyss, AP8    Stella, PJ9    Schild, SE10    Molina, JR11    Adjei, AA.12
  • 58
    • 84857838650 scopus 로고    scopus 로고
    • Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent nonsmall cell lung cancer (NSCLC): PrECOG PrE0501 update on maintenance treatment, progression-free survival (PFS), and overall survival (OS)
    • Aisner J, Manola J, Dakhil SR, Stella PJ, Schiller JH. Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent nonsmall cell lung cancer (NSCLC): PrECOG PrE0501 update on maintenance treatment, progression-free survival (PFS), and overall survival (OS). J Clin Oncol. 2011; 29:7560.
    • (2011) J Clin Oncol , vol.29 , pp. 7560
    • Aisner, J1    Manola, J2    Dakhil, SR3    Stella, PJ4    Schiller, JH.5
  • 63
    • 84857871901 scopus 로고    scopus 로고
    • A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study
    • Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, Aubry M, Flynn PJ, Mandrekar SJ, Schild SE, Adjei AA. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol. 2011; 29:7513.
    • (2011) J Clin Oncol , vol.29 , pp. 7513
    • Molina, JR1    Dy, GK2    Foster, NR3    Allen Ziegler, KL4    Adjei, A5    Rowland, KM6    Aubry, M7    Flynn, PJ8    Mandrekar, SJ9    Schild, SE10    Adjei, AA.11
  • 64
    • 84893413347 scopus 로고    scopus 로고
    • CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer
    • Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014; 9:214-221.
    • (2014) J Thorac Oncol , vol.9 , pp. 214-221
    • Heist, RS1    Wang, X2    Hodgson, L3    Otterson, GA4    Stinchcombe, TE5    Gandhi, L6    Villalona-Calero, MA7    Watson, P8    Vokes, EE9    Socinski, MA.10
  • 65
    • 77954035012 scopus 로고    scopus 로고
    • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
    • Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010; 11:619-626.
    • (2010) Lancet Oncol , vol.11 , pp. 619-626
    • Herbst, RS1    Sun, Y2    Eberhardt, WE3    Germonpré, P4    Saijo, N5    Zhou, C6    Wang, J7    Li, L8    Kabbinavar, F9    Ichinose, Y10    Qin, S11    Zhang, L12    Biesma, B13
  • 68
    • 84994609086 scopus 로고    scopus 로고
    • Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
    • Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer. 2016; 102:65-73.
    • (2016) Lung Cancer , vol.102 , pp. 65-73
    • Hanna, NH1    Kaiser, R2    Sullivan, RN3    Aren, OR4    Ahn, MJ5    Tiangco, B6    Voccia, I7    Pawel, JV8    Kovcin, V9    Agulnik, J10    Gaschler-Markefski, B11    Barrueco, J12    Sikken, P13
  • 69
    • 32344443105 scopus 로고    scopus 로고
    • China offers alternative gateway for experimental drugs
    • Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol. 2006; 24:117-118.
    • (2006) Nat Biotechnol , vol.24 , pp. 117-118
    • Jia, H1    Kling, J.2
  • 70
    • 23944472880 scopus 로고    scopus 로고
    • Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients
    • [Article in Chinese]
    • Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, Zhu Y, Zhou Q, Hou M, Guan Z, Li W, Zhuang W, Wang D, et al. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. [Article in Chinese]. Zhongguo fei ai za zhi. 2005; 8:283-290.
    • (2005) Zhongguo fei ai za zhi , vol.8 , pp. 283-290
    • Wang, J1    Sun, Y2    Liu, Y3    Yu, Q4    Zhang, Y5    Li, K6    Zhu, Y7    Zhou, Q8    Hou, M9    Guan, Z10    Li, W11    Zhuang, W12    Wang, D13
  • 71
    • 79958178412 scopus 로고    scopus 로고
    • A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer
    • Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6:1104-1109.
    • (2011) J Thorac Oncol , vol.6 , pp. 1104-1109
    • Han, B1    Xiu, Q2    Wang, H3    Shen, J4    Gu, A5    Luo, Y6    Bai, C7    Guo, S8    Liu, W9    Zhuang, Z10    Zhang, Y11    Zhao, Y12    Jiang, L13
  • 72
    • 84865281099 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
    • Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 2012; 10:170.
    • (2012) World J Surg Oncol , vol.10 , pp. 170
    • Rong, B1    Yang, S2    Li, W3    Zhang, W4    Ming, Z.5
  • 74
    • 0037341379 scopus 로고    scopus 로고
    • Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice
    • Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res. 2003; 9:1200-1210.
    • (2003) Clin Cancer Res , vol.9 , pp. 1200-1210
    • Kim, SJ1    Uehara, H2    Karashima, T3    Shepherd, DL4    Killion, JJ5    Fidler, IJ.6
  • 75
    • 0037386774 scopus 로고    scopus 로고
    • Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
    • Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003; 9:1546-1556.
    • (2003) Clin Cancer Res , vol.9 , pp. 1546-1556
    • Ciardiello, F1    Caputo, R2    Damiano, V3    Caputo, R4    Troiani, T5    Vitagliano, D6    Carlomagno, F7    Veneziani, BM8    Fontanini, G9    Bianco, AR10    Tortora, G.11
  • 76
    • 84908127948 scopus 로고    scopus 로고
    • Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
    • Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15:1236-1244.
    • (2014) Lancet Oncol , vol.15 , pp. 1236-1244
    • Seto, T1    Kato, T2    Nishio, M3    Goto, K4    Atagi, S5    Hosomi, Y6    Yamamoto, N7    Hida, T8    Maemondo, M9    Nakagawa, K10    Nagase, S11    Okamoto, I12    Yamanaka, T13
  • 77
    • 84975183505 scopus 로고    scopus 로고
    • A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
    • abstr 3BA
    • Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, et al. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Ann Oncol. 2015; abstr 3BA.
    • (2015) Ann Oncol
    • Stahel, RA1    Dafni, U2    Gautschi, O3    Felip, E4    Curioni-Fontecedro, A5    Peters, S6    Massutí, B7    Cardenal, F8    Aix, SP9    Früh, M10    Pless, M11    Popat, S12    Kotsakis, A13
  • 78
    • 84938275519 scopus 로고    scopus 로고
    • Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001
    • Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Ooncol. 2015; 10:486-491.
    • (2015) J Thorac Ooncol , vol.10 , pp. 486-491
    • Ichihara, E1    Hotta, K2    Nogami, N3    Kuyama, S4    Kishino, D5    Fujii, M6    Kozuki, T7    Tabata, M8    Harada, D9    Chikamori, K10    Aoe, K11    Ueoka, H12    Hosokawa, S13
  • 79
    • 84891656497 scopus 로고    scopus 로고
    • ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
    • Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013; 31:3926-3934.
    • (2013) J Clin Oncol , vol.31 , pp. 3926-3934
    • Johnson, BE1    Kabbinavar, F2    Fehrenbacher, L3    Hainsworth, J4    Kasubhai, S5    Kressel, B6    Lin, CY7    Marsland, T8    Patel, T9    Polikoff, J10    Rubin, M11    White, L12    Yang, JC13
  • 80
    • 79957823572 scopus 로고    scopus 로고
    • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
    • Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011; 377:1846-1854.
    • (2011) Lancet , vol.377 , pp. 1846-1854
    • Herbst, RS1    Ansari, R2    Bustin, F3    Flynn, P4    Hart, L5    Otterson, GA6    Vlahovic, G7    Soh, CH8    O'Connor, P9    Hainsworth, J.10
  • 82
    • 84975498256 scopus 로고    scopus 로고
    • BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer
    • Gridelli C, Rossi A, Ciardiello F, De Marinis F, Crinò L, Morabito A, Morgillo F, Montanino A, Daniele G, Piccirillo MC, Normanno N, Gallo C, Perrone F. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016; 17:461-465.
    • (2016) Clin Lung Cancer , vol.17 , pp. 461-465
    • Gridelli, C1    Rossi, A2    Ciardiello, F3    De Marinis, F4    Crinò, L5    Morabito, A6    Morgillo, F7    Montanino, A8    Daniele, G9    Piccirillo, MC10    Normanno, N11    Gallo, C12    Perrone, F.13
  • 83
    • 85007291864 scopus 로고    scopus 로고
    • Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer
    • Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Clin lung cancer. 2016; 18:96-99.
    • (2016) Clin lung cancer , vol.18 , pp. 96-99
    • Garon, EB1    Reck, M2    Paz-Ares, L3    Ponce, S4    Jaime, JC5    Juan, O6    Nadal, E7    Lee, P8    Dalal, R9    Liu, J10    He, S11    Treat, J12    Nakagawa, K.13
  • 85
    • 84883360843 scopus 로고    scopus 로고
    • A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic nonsmall-cell lung cancer (NSCLC)
    • Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic nonsmall-cell lung cancer (NSCLC). Ann Oncol. 2013; 24:2382-2389.
    • (2013) Ann Oncol , vol.24 , pp. 2382-2389
    • Groen, HJ1    Socinski, MA2    Grossi, F3    Juhasz, E4    Gridelli, C5    Baas, P6    Butts, CA7    Chmielowska, E8    Usari, T9    Selaru, P10    Harmon, C11    Williams, JA12    Gao, F13
  • 87
    • 85101803225 scopus 로고    scopus 로고
    • Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations
    • abstr e20074
    • Zhao Q, Peng L, Chen F, Hong Z, Mou H, Wang Y, Tang Y, Liu J. Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations. J Clin Oncol. 2016; abstr e20074.
    • (2016) J Clin Oncol
    • Zhao, Q1    Peng, L2    Chen, F3    Hong, Z4    Mou, H5    Wang, Y6    Tang, Y7    Liu, J.8
  • 90
    • 84950117835 scopus 로고    scopus 로고
    • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    • Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387:1540-1550.
    • (2016) Lancet , vol.387 , pp. 1540-1550
    • Herbst, RS1    Baas, P2    Kim, DW3    Felip, E4    Pérez-Gracia, JL5    Han, JY6    Molina, J7    Kim, JH8    Arvis, CD9    Ahn, MJ10    Majem, M11    Fidler, MJ12    de Castro, G13
  • 93
    • 84876717683 scopus 로고    scopus 로고
    • Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
    • Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, Yagita H, Nakajima Y. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol. 2013; 172:500-506.
    • (2013) Clin Exp Immunol , vol.172 , pp. 500-506
    • Yasuda, S1    Sho, M2    Yamato, I3    Yoshiji, H4    Wakatsuki, K5    Nishiwada, S6    Yagita, H7    Nakajima, Y.8
  • 96
    • 84991455944 scopus 로고    scopus 로고
    • Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines
    • Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res. 2014; 2:1090-1102.
    • (2014) Cancer Immunol Res , vol.2 , pp. 1090-1102
    • Farsaci, B1    Donahue, RN2    Coplin, MA3    Grenga, I4    Lepone, LM5    Molinolo, AA6    Hodge, JW.7
  • 97
    • 33845343558 scopus 로고    scopus 로고
    • Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy
    • Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006; 12:6808-6816.
    • (2006) Clin Cancer Res , vol.12 , pp. 6808-6816
    • Li, B1    Lalani, AS2    Harding, TC3    Luan, B4    Koprivnikar, K5    Huan Tu, G6    Prell, R7    VanRoey, MJ8    Simmons, AD9    Jooss, K.10
  • 98
    • 84946240266 scopus 로고    scopus 로고
    • Nivolumab (Anti-PD-1; BMS-936558, ONO- 4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
    • Rizvi NA, Antonia SJ, Shepherd FA, Chow LQ, Goldman J, Shen Y, Chen AC, Getting S. Nivolumab (Anti-PD-1; BMS-936558, ONO- 4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy. Radiation Oncol. 2014; 90:S32.
    • (2014) Radiation Oncol , vol.90 , pp. S32
    • Rizvi, NA1    Antonia, SJ2    Shepherd, FA3    Chow, LQ4    Goldman, J5    Shen, Y6    Chen, AC7    Getting, S.8
  • 100
    • 84949959569 scopus 로고    scopus 로고
    • Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC)
    • abstr 410
    • Sznol M, McDermott DF, Jones SF, Mier JW, Waterkamp D, Rossi C, Wallin J, Funke RP, Bendell JC. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2015; abstr 410.
    • (2015) J Clin Oncol
    • Sznol, M1    McDermott, DF2    Jones, SF3    Mier, JW4    Waterkamp, D5    Rossi, C6    Wallin, J7    Funke, RP8    Bendell, JC.9
  • 104
    • 85013118657 scopus 로고    scopus 로고
    • A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, nonsmall cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
    • abstr 3056
    • Herbst RS, Bendell JC, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia JL, Yang J, Rege J, Ferry D, Mi G, Chau I. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, nonsmall cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. J Clin Oncol. 2016; abstr 3056.
    • (2016) J Clin Oncol
    • Herbst, RS1    Bendell, JC2    Isambert, N3    Calvo, E4    Santana-Davila, R5    Cassier, P6    Perez-Gracia, JL7    Yang, J8    Rege, J9    Ferry, D10    Mi, G11    Chau, I.12
  • 106
    • 77649213706 scopus 로고    scopus 로고
    • Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
    • Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28:780-7.
    • (2010) J Clin Oncol , vol.28 , pp. 780-787
    • Spratlin, JL1    Cohen, RB2    Eadens, M3    Gore, L4    Camidge, DR5    Diab, S6    Leong, S7    O'Bryant, C8    Chow, LQ9    Serkova, NJ10    Meropol, NJ11    Lewis, NL12    Chiorean, EG13
  • 107
    • 84947943267 scopus 로고    scopus 로고
    • Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
    • Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J Thorac Oncol. 2015; 10:1745-1753.
    • (2015) J Thorac Oncol , vol.10 , pp. 1745-1753
    • Paz-Ares, L1    Hirsh, V2    Zhang, L3    de Marinis, F4    Yang, JC5    Wakelee, HA6    Seto, T7    Wu, YL8    Novello, S9    Juhász, E10    Arén, O11    Sun, Y12    Schmelter, T13
  • 108
    • 84861720010 scopus 로고    scopus 로고
    • Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)
    • Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012; 30:1114-1121.
    • (2012) J Clin Oncol , vol.30 , pp. 1114-1121
    • Lee, JS1    Hirsh, V2    Park, K3    Qin, S4    Blajman, CR5    Perng, RP6    Chen, YM7    Emerson, L8    Langmuir, P9    Manegold, C.10
  • 109
    • 84894244012 scopus 로고    scopus 로고
    • A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)
    • Zhou Q, Zhou CC, Chen GY, Cheng Y, Huang C, Zhang L, Xu CR, Li AW, Yan HH, Su J, Zhang XC, Yang JJ, Wu YL. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung cancer. 2014; 83:369-373.
    • (2014) Lung cancer , vol.83 , pp. 369-373
    • Zhou, Q1    Zhou, CC2    Chen, GY3    Cheng, Y4    Huang, C5    Zhang, L6    Xu, CR7    Li, AW8    Yan, HH9    Su, J10    Zhang, XC11    Yang, JJ12    Wu, YL.13
  • 110
    • 70349304196 scopus 로고    scopus 로고
    • Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer
    • Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27:4274-4280.
    • (2009) J Clin Oncol , vol.27 , pp. 4274-4280
    • Blumenschein, GR1    Gatzemeier, U2    Fossella, F3    Stewart, DJ4    Cupit, L5    Cihon, F6    O'Leary, J7    Reck, M.8
  • 111
    • 84866625336 scopus 로고    scopus 로고
    • A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501
    • Wakelee HA, Lee JW, Hanna NH, Traynor AM, Carbone DP, Schiller JH. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol. 2012; 7:1574-1582.
    • (2012) J Thorac Oncol , vol.7 , pp. 1574-1582
    • Wakelee, HA1    Lee, JW2    Hanna, NH3    Traynor, AM4    Carbone, DP5    Schiller, JH.6
  • 113
    • 79957452054 scopus 로고    scopus 로고
    • A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
    • Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011; 22:1374-1381.
    • (2011) Ann Oncol , vol.22 , pp. 1374-1381
    • Reck, M1    Kaiser, R2    Eschbach, C3    Stefanic, M4    Love, J5    Gatzemeier, U6    Stopfer, P7    von Pawel, J.8
  • 115
    • 84892808887 scopus 로고    scopus 로고
    • A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens
    • abstr 7548
    • Zhang L, Shi M, Huang C, Liu X, Xiong J, Chen G, Liu W, Liu W, Zhang Y, Li K, Yu H, Jiang H. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol. 2012; abstr 7548.
    • (2012) J Clin Oncol
    • Zhang, L1    Shi, M2    Huang, C3    Liu, X4    Xiong, J5    Chen, G6    Liu, W7    Liu, W8    Zhang, Y9    Li, K10    Yu, H11    Jiang, H.12
  • 116
    • 84950120863 scopus 로고    scopus 로고
    • Anti-angiogenesis in personalized therapy of lung cancer
    • Ellis PM. Anti-angiogenesis in personalized therapy of lung cancer. Adv Exp Med Biol. 2016; 893:91-126.
    • (2016) Adv Exp Med Biol , vol.893 , pp. 91-126
    • Ellis, PM.1
  • 117
    • 84947966922 scopus 로고    scopus 로고
    • New antiangiogenetic therapy beyond bevacizumab in the treatment of advanced non small cell lung cancer
    • Sacco PC, Maione P, Rossi A, Sgambato A, Casaluce F, Palazzolo G, Gridelli C. New antiangiogenetic therapy beyond bevacizumab in the treatment of advanced non small cell lung cancer. Curr Pharm Des. 2015; 21:4763-4772.
    • (2015) Curr Pharm Des , vol.21 , pp. 4763-4772
    • Sacco, PC1    Maione, P2    Rossi, A3    Sgambato, A4    Casaluce, F5    Palazzolo, G6    Gridelli, C.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.